Valuation Gilead Sciences, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 20:55:44 11/09/2024 BST			5-day change	1st Jan Change
80.94 ^USD	-0.62%		+2.04%	-0.33%

08:54pm	Raymond James Raises Gilead Sciences' Price Target to $94 From $93, Outperform Rating Maintained	MT
09-10	Transcript : Gilead Sciences, Inc. Presents at Baird's 2024 Global Healthcare Conference, Sep-10-2024 10:50 AM

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	82,209	73,031	91,081	107,677	100,942	101,392	-	-
Change	-	-11.16%	24.72%	18.22%	-6.25%	0.45%	-	-
Enterprise Value (EV) ¹	82,450	103,910	118,530	126,522	118,665	118,545	113,880	108,461
Change	-	26.03%	14.07%	6.74%	-6.21%	-0.1%	-3.94%	-4.76%
P/E ratio	15.4x	583x	14.7x	23.6x	18x	303x	15.8x	14.3x
PBR	3.65x	4.04x	4.32x	5.05x	4.48x	5.15x	4.57x	4.03x
PEG	-	-6x	0x	-0.9x	0.8x	-3.2x	0x	1.3x
Capitalization / Revenue	3.66x	2.96x	3.34x	3.95x	3.72x	3.66x	3.62x	3.52x
EV / Revenue	3.67x	4.21x	4.34x	4.64x	4.38x	4.28x	4.07x	3.77x
EV / EBITDA	6.61x	7.88x	8.12x	8.86x	9.01x	11.8x	8.12x	7.66x
EV / EBIT	7.45x	8.88x	9.45x	10.4x	11.3x	16x	9.66x	8.89x
EV / FCF	9.91x	13.8x	11x	15.2x	16x	14.8x	11.1x	10.4x
FCF Yield	10.1%	7.24%	9.12%	6.59%	6.25%	6.73%	9.02%	9.62%
Dividend per Share ²	2.52	2.72	2.84	2.92	3	3.076	3.233	3.379
Rate of return	3.88%	4.67%	3.91%	3.4%	3.7%	3.78%	3.97%	4.15%
EPS ²	4.22	0.1	4.93	3.64	4.5	0.2692	5.164	5.715
Distribution rate	59.7%	2,720%	57.6%	80.2%	66.7%	1,143%	62.6%	59.1%
Net sales ¹	22,449	24,689	27,305	27,281	27,116	27,710	27,986	28,789
EBITDA ¹	12,468	13,184	14,598	14,283	13,177	10,081	14,023	14,167
EBIT ¹	11,064	11,704	12,548	12,180	10,484	7,415	11,783	12,206
Net income ¹	5,386	123	6,225	4,592	5,665	185.5	6,573	6,911
Net Debt ¹	241	30,879	27,449	18,845	17,723	17,153	12,488	7,069
Reference price ²	64.98	58.26	72.61	85.85	81.01	81.44	81.44	81.44
Nbr of stocks (in thousands)	1,265,146	1,253,528	1,254,384	1,254,244	1,246,042	1,244,992	-	-
Announcement Date	04/02/20	04/02/21	01/02/22	02/02/23	06/02/24	-	-	-

¹USD in Million²USD

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
GILEAD SCIENCES, INC.	302.53x	4.28x	11.76x	+3.78%	101B
ELI LILLY AND COMPANY	58.11x	18.01x	43.74x	+0.58%	812B
NOVO NORDISK A/S	38.54x	13.43x	27.34x	+1.30%	573B
JOHNSON & JOHNSON	21.43x	4.63x	13.14x	+2.80%	403B
ABBVIE INC.	38.8x	7.32x	15.82x	+3.13%	352B
MERCK & CO., INC.	15.38x	4.89x	11.2x	+2.67%	292B
ASTRAZENECA PLC	28.97x	5.21x	15.46x	+1.91%	251B
ROCHE HOLDING AG	16.05x	3.81x	9.97x	+3.66%	255B
NOVARTIS AG	21.08x	4.99x	12.63x	+3.24%	236B
AMGEN INC.	50.67x	6.84x	11.97x	+2.79%	177B
Average	59.16x	7.34x	17.30x	+2.58%	345.32B
Weighted average by Cap.	44.03x	9.64x	22.60x	+2.11%